These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 17956343)

  • 21. Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis.
    Crick DC; Mahapatra S; Brennan PJ
    Glycobiology; 2001 Sep; 11(9):107R-118R. PubMed ID: 11555614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure, function and biogenesis of the mycobacterial cell wall.
    Brennan PJ; Besra GS
    Biochem Soc Trans; 1997 Feb; 25(1):188-94. PubMed ID: 9056869
    [No Abstract]   [Full Text] [Related]  

  • 23. A Review on Benzimidazole Scaffolds as Inhibitors of
    Bhaskar V; Kumar S; Nair AS; Rajappan KP; Sudevan ST; Parambi DGT; Al-Sehemi AG; Zachariah SM; Pappachen LK
    Comb Chem High Throughput Screen; 2023; 26(4):668-681. PubMed ID: 35430964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.
    Jackson M; McNeil MR; Brennan PJ
    Future Microbiol; 2013 Jul; 8(7):855-75. PubMed ID: 23841633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural and functional features of enzymes of Mycobacterium tuberculosis peptidoglycan biosynthesis as targets for drug development.
    Moraes GL; Gomes GC; Monteiro de Sousa PR; Alves CN; Govender T; Kruger HG; Maguire GE; Lamichhane G; Lameira J
    Tuberculosis (Edinb); 2015 Mar; 95(2):95-111. PubMed ID: 25701501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered expression profile of the surface glycopeptidolipids in drug-resistant clinical isolates of Mycobacterium avium complex.
    Khoo KH; Jarboe E; Barker A; Torrelles J; Kuo CW; Chatterjee D
    J Biol Chem; 1999 Apr; 274(14):9778-85. PubMed ID: 10092667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revisiting Anti-tuberculosis Therapeutic Strategies That Target the Peptidoglycan Structure and Synthesis.
    Catalão MJ; Filipe SR; Pimentel M
    Front Microbiol; 2019; 10():190. PubMed ID: 30804921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell Surface Biosynthesis and Remodeling Pathways in Mycobacteria Reveal New Drug Targets.
    Shaku M; Ealand C; Kana BD
    Front Cell Infect Microbiol; 2020; 10():603382. PubMed ID: 33282752
    [No Abstract]   [Full Text] [Related]  

  • 29. Peptidoglycan Hydrolases RipA and Ami1 Are Critical for Replication and Persistence of Mycobacterium tuberculosis in the Host.
    Healy C; Gouzy A; Ehrt S
    mBio; 2020 Mar; 11(2):. PubMed ID: 32127458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The C-terminal domain of the Arabinosyltransferase Mycobacterium tuberculosis EmbC is a lectin-like carbohydrate binding module.
    Alderwick LJ; Lloyd GS; Ghadbane H; May JW; Bhatt A; Eggeling L; Fütterer K; Besra GS
    PLoS Pathog; 2011 Feb; 7(2):e1001299. PubMed ID: 21383969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assembling of the Mycobacterium tuberculosis Cell Wall Core.
    Grzegorzewicz AE; de Sousa-d'Auria C; McNeil MR; Huc-Claustre E; Jones V; Petit C; Angala SK; Zemanová J; Wang Q; Belardinelli JM; Gao Q; Ishizaki Y; Mikušová K; Brennan PJ; Ronning DR; Chami M; Houssin C; Jackson M
    J Biol Chem; 2016 Sep; 291(36):18867-79. PubMed ID: 27417139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and antituberculosis activity of C-phosphonate analogues of decaprenolphosphoarabinose, a key intermediate in the biosynthesis of mycobacterial arabinogalactan and lipoarabinomannan.
    Centrone CA; Lowary TL
    J Org Chem; 2002 Dec; 67(25):8862-70. PubMed ID: 12467400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R; Zahra NU; Azam SS
    Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status and future development of antitubercular chemotherapy.
    Kremer LS; Besra GS
    Expert Opin Investig Drugs; 2002 Aug; 11(8):1033-49. PubMed ID: 12150700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unraveling the Structure of the Mycobacterial Envelope.
    Daffé M; Marrakchi H
    Microbiol Spectr; 2019 Jul; 7(4):. PubMed ID: 31267927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An approach for the rational design of new antituberculosis agents.
    Pasqualoto KF; Ferreira EI
    Curr Drug Targets; 2001 Dec; 2(4):427-37. PubMed ID: 11732641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis.
    Bhat ZS; Rather MA; Maqbool M; Lah HU; Yousuf SK; Ahmad Z
    Biomed Pharmacother; 2017 Nov; 95():1520-1534. PubMed ID: 28946393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring Targets of Cell Wall Protein Synthesis and Overexpression Mediated Drug Resistance for the Discovery of Potential M. tb Inhibitors.
    Nandi S; Saxena AK
    Curr Top Med Chem; 2021; 21(21):1922-1942. PubMed ID: 34315374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deletion of Cg-emb in corynebacterianeae leads to a novel truncated cell wall arabinogalactan, whereas inactivation of Cg-ubiA results in an arabinan-deficient mutant with a cell wall galactan core.
    Alderwick LJ; Radmacher E; Seidel M; Gande R; Hitchen PG; Morris HR; Dell A; Sahm H; Eggeling L; Besra GS
    J Biol Chem; 2005 Sep; 280(37):32362-71. PubMed ID: 16040600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.